Solutions - Page 5

AdvanCell, a clinical-stage radiopharmaceutical outfit, inked a lease near Boston to produce its prostate cancer candidate and set roots down for its U.S. headquarters.

Most of those two weeks is not science. It is finding and assembling the data, which is also where most of the AI sold to pharma quietly stalls.

With interest in automated cell therapy production beginning to build from about 2016 onward, some 23 companies working in the field have now raised a collective $1.1 billion across 34 rounds through

Eighteen months after Novo Nordisk purchased a plant in the Czech Republic from Novavax, the Danish drugmaker said it is set to kick off the manufacturing of ingredients for next-generation diabetes and

Recipharm has sketched out a “multi-million-dollar” investment in its U.S. manufacturing operations as part of a move to boost its sterile fill-finish capabilities and other production offerings for customers.

As the United Kingdom juggles industry concerns about the region’s waning appeal and competitiveness, Eisai is getting a lift from a production-tinged fund that the British government first unveiled in 2024.

Teva plans to remove 250 jobs at its CDMO unit over the next two years, Israeli business news outlet Globes reports.

Hikma Pharmaceuticals plans to spend $267 million to expand a pair of manufacturing facilities in Ohio as part of the $1 billion the U.K. drugmaker committed a year ago to build out

Medical device distribution giant Medline has been slammed for a second time since April by an FDA warning letter that has chided the company for repeated problems centered on the presence of

Cingulate will need to take a detour to win its first FDA approval, as the agency has rejected its lead candidate over manufacturing concerns.